In Alzheimer's there was no treatment like there is for mTNBC. What it would take for patient advocacy in breast cancer would be great results in a larger trial that are published in a peer reviewed article. That won't happen until phase 3 interim. What would work against that is that many advocacy groups receive funding from BP.

The FDA's excuse of advocacy for aduhelm was ridiculous. What is the FDA going to say to the families of those harmed or killed from using aduhelm "sorry your parents died but you're the ones who asked for it.".